ClinicalTrials.gg
Active, not recruitingNCT02337244Updated Nov 25, 2025

Zimmer POLAR Persona - TKA (EMEA Study)

An observational study in Severe Knee Pain, Severe Knee Disability and Osteoarthritis, sponsored by Zimmer, GmbH. Active, not recruiting at 12 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Zimmer, GmbH · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
777
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 101 studies in Osteoarthritis by Zimmer Biomet — 4 open to participants now, 24 under way, none of them phase 3. Osteoarthritis · Zimmer Biomet.

Enrollment
Largest of 53
777 · median 118
Started
2013
with 11 others
Observational
53 of 101
3 open now
Primary completion
2026-12
later than 3 of 23 live
Registered
60th of 101
by date

Among the 101 studies in Osteoarthritis by Zimmer Biomet, this one has the largest enrollment of the 53 observational ones that give a count, is one of 12 that started in 2013, is one of 53 observational ones, reaches primary completion later than 3 of the 23 other live ones, and was the 60th registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

4 of the 101 studies in Osteoarthritis by Zimmer Biomet are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 284 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Osteoarthritis by Zimmer Biomet, or all of them as a file.
02

Study summary

The primary objective of this study is to obtain implant survivorship and clinical outcomes data for commercially available Persona knee implants used in primary total knee arthroplasty. The assessment will include:

  1. Implant survivorship based on removal of a study device.
  2. Safety based on incidence and frequency of adverse events.
  3. Clinical performance measured by overall pain and function, quality of life data, radiographic parameters and survivorship.
Read the detailed description

This is a prospective, multicenter, non-controlled study of the commercially available Persona knee implants. The study will require each site to obtain Ethics approval prior to study enrollment. All potential study subjects will be required to participate in the Informed Consent Process.

Study subjects will undergo preoperative clinical evaluations prior to their total knee arthroplasty. The post-operative clinical and radiographic evaluations will be conducted at 5 days to 6 weeks, 3 to 6 months, 1 year, 2, 3, 4, and 5 years after implantation. The hospital CHU Clermont-Ferrand, France with PI Prof. Boisgard will conduct additional 7 (voluntary) and 10 years (standard of care) follow-up visits.

03

Conditions studied

  • Severe Knee Pain
  • Severe Knee Disability
  • Osteoarthritis
  • Rheumatoid Arthritis
  • Traumatic Arthritis
  • Polyarthritis

Keywords

  • Osteoarthritis
  • Rheumatoid arthritis
  • Traumatic arthritis
  • Polyarthritis
  • Total knee arthroplasty
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Primary total knee arthroplasty subjects that receive the Zimmer Persona Total Knee System.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient 18-75 years of age, inclusive.
  • Patient qualifies for primary total knee arthroplasty based on physical exam and medical history, including diagnosis of severe knee pain and disability due to at least one of the following:

    • rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis;
    • collagen disorders and/or avascular necrosis of the femoral condyle;
    • post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy;
    • moderate valgus, varus, or flexion deformities;
    • the salvage of previously failed surgical attempts that did not include partial or total knee arthroplasty of the ipsilateral knee.
  • Patient is willing and able to complete scheduled study procedures and follow-up evaluations.
  • Independent of study participation, patient is a candidate for commercially available Zimmer Persona knee implants implanted in accordance with product labeling.

Exclusion criteria

Exclusion Criteria:

  • Patient is currently participating in any other surgical intervention studies or pain management studies.
  • Previous history of infection in the affected joint and/or other local/systemic infection that may affect the prosthetic joint.
  • Insufficient bone stock on femoral or tibial surfaces.
  • Skeletal immaturity.
  • Neuropathic arthropathy.
  • Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb.
  • Stable, painless arthrodesis in a satisfactory functional position.
  • Severe instability secondary to the absence of collateral ligament integrity.
  • Rheumatoid arthritis accompanied by an ulcer of the skin or a history of recurrent breakdown of the skin.
  • Patient has a known or suspected sensitivity or allergy to one or more of the implant materials.
  • Patient is pregnant or considered a member of a protected population (e.g., prisoner, mentally incompetent, etc.).
  • Patient has previously received partial or total knee arthroplasty for the ipsilateral knee.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
777 participants (actual)
Patient registry
No

Interventions

  • DeviceZimmer Persona Total Knee System

    No Intervention

    Also known as: Primary Knee Replacement, Total Knee Arthroplasty, Total Knee Replacement

06

What researchers measure

Primary outcomes

  1. Kaplan-Meier Implant Survivorship

    Kaplan-Meier survivorship at 5 years with revision of any implant component, for any reason, as endpoint.

    Time frame: 5 years

Secondary outcomes

  1. 'Knee injury and Osteoarthritis Outcome Score' (KOOS) subscale scores.

    The scores related to the five KOOS subscales calculated at different time points until 5 years.

    Time frame: 5 years

  2. 'Forgotten Joint Score' (FJS-12)

    The score related to the FJS-12 patient-reported questionaire calculated at different time points until 5 years.

    Time frame: 5 years

  3. Oxford Knee Score (OKS)

    The score related to the OKS patient-reported questionaire calculated at different time points until 5 years.

    Time frame: 5 years

  4. EuroQol (EQ)-5D-3L score and EQ 'Visual Analog Scale' (VAS)

    The scores related to the EQ-5D-3L questionnaire and the EQ-VAS calculated at different time points until 5 years.

    Time frame: 5 years

07

Study locations

12 sites
08

References and documents

Publications

  • Mathijssen NMC, Verburg H, London NJ, Landsiedl M, Dominkus M. Patient reported outcomes and implant survivorship after Total knee arthroplasty with the persona knee implant system: two year follow up. BMC Musculoskelet Disord. 2019 Mar 4;20(1):97. doi: 10.1186/s12891-019-2470-y. PubMed 30832636 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2013 (actual). Primary completion is estimated for Dec 2026, 157 months after the start.

Of 82 industry-sponsored observational studies under Osteoarthritis, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 184. This study's planned 157 months is above that.

Counting every sponsor, half of 228 studies reached it within 57 months; a quarter within 21 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2015
First posted
Jan 13, 2015
StartActual
Nov 18, 2013
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02337244
Lead sponsor
Zimmer, GmbH
Responsible party
Sponsor
First posted
Jan 13, 2015
Start date
Nov 18, 2013
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 25, 2025

Study contacts

Martin Dominkus, MD
principal investigator · Orthopädisches Spital Speising, Wien, Austria
Hendrik Verburg, MD
principal investigator · Stichting Research Orthopedie & Reinier de Graaf Groep, Delf, Netherlands
Nicholas London, MD
principal investigator · Harrogate and District NHS, Harrogate, England
Stéphane Boisgard, MD
principal investigator · CHU de Clermont-Ferrand, Clermont-Ferrand, France
François Canovas, Prof
principal investigator · Hospital Lapeyronie, Montpellier
Pere Torner, MD
principal investigator · Hospital Parc Tauli, Sabadell
Jon Clarke, MD
principal investigator · Golden Jubilee National Hospital, Clydebank
David Deehan, Prof
principal investigator · Freeman Hospital, Newcastle
Karl Dieter Heller, Prof
principal investigator · HEH Braunschweig
Fritz Thorey, Prof
principal investigator · Atos Klinik Heidelberg
Fernando Martinez Delgado, MD
principal investigator · Hospital Miguel Servet Zaragoza
Hermant Pandit, Prof
principal investigator · University of Leeds

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion